FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386319762> ?p ?o ?g. }

• W4386319762 endingPage "155062" @default.
• W4386319762 startingPage "155062" @default.
• W4386319762 abstract "Icaritin has a wide range of pharmacological activities, including significant an-titumor activity. However, the mechanism of action of icaritin in endometrial cancer (UCEC) remains unknown. FOX proteins are a highly conserved transcription factor superfamily that play important roles in epithelial cell differentiation, tumor metastasis, angiogenesis, and cell cycle regulation. FOXC1 is an important member of the FOX protein family. FOXC1 is aberrantly expressed in endometrial cancer and may play a role in the migration and invasion of endometrial cancer; however, its mechanism of action has not yet been reported. O-GlcNAc glycosylation is a common post-translational modification. In endometrial cancer, high levels of O-GlcNAcylation promote cell proliferation, migration, and invasion. Cancer development is often accompanied by O-GlcNAc modification of proteins; however, O-GlcNAc modification of the transcription factor FOXC1 has not been reported to date. To investigate the inhibitory effects of icaritin on RL95-2 and Ishikawa endometrial cancer cells in vitro and in vivo and to elucidate the possible molecular mechanisms. CCK8, colony formation, migration, and invasion assays were used to determine the inhibitory effects of icaritin on endometrial cancer cells in vitro. Cell cycle regulation was assayed by flow cytometry. Protein levels were measured based on western blotting. The level of FOXC1 expression in endometrial cancer tissues was determined by immunohistochemistry. To assess whether icaritin also has activity in vivo, its effect on tumor xenografts was evaluated. Immunohistochemical analysis of clinical samples revealed that FOXC1 expression was significantly higher in endometrial cancer tissues than in normal tissues. Downregulation of FOXC1 inhibited the proliferative, colony formation, migration, and invasive abilities of RL95-2 and Ishikawa endometrial cancer cells. Icaritin inhibited the proliferation, colony formation, migration, and invasion of endometrial cancer cells and blocked the cell cycle in S phase. Icaritin affected O-GlcNAc modification of FOXC1 and thus the stability of FOXC1, which subsequently triggered the inhibition of endometrial cancer cell proliferation. The anti-endometrial cancer effect of icaritin is related to the inhibition of abnormal O-GlcNAc modification of FOXC1, which may provide an important theoretical foundation for the use of icaritin against endometrial cancer." @default.
• W4386319762 created "2023-09-01" @default.
• W4386319762 creator A5003580554 @default.
• W4386319762 creator A5011435455 @default.
• W4386319762 creator A5028121388 @default.
• W4386319762 creator A5030921116 @default.
• W4386319762 creator A5035182164 @default.
• W4386319762 creator A5063103450 @default.
• W4386319762 date "2023-11-01" @default.
• W4386319762 modified "2023-10-14" @default.
• W4386319762 title "Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1" @default.
• W4386319762 cites W1990319711 @default.
• W4386319762 cites W2027952623 @default.
• W4386319762 cites W2055579227 @default.
• W4386319762 cites W2077719385 @default.
• W4386319762 cites W2121232832 @default.
• W4386319762 cites W2172247109 @default.
• W4386319762 cites W2207803749 @default.
• W4386319762 cites W2268193501 @default.
• W4386319762 cites W2594279019 @default.
• W4386319762 cites W2596882124 @default.
• W4386319762 cites W2768800571 @default.
• W4386319762 cites W2792586190 @default.
• W4386319762 cites W2796078761 @default.
• W4386319762 cites W2807059865 @default.
• W4386319762 cites W2809778923 @default.
• W4386319762 cites W2884876549 @default.
• W4386319762 cites W2891807177 @default.
• W4386319762 cites W2912936715 @default.
• W4386319762 cites W2970155667 @default.
• W4386319762 cites W3044555879 @default.
• W4386319762 cites W3142553327 @default.
• W4386319762 cites W3146492162 @default.
• W4386319762 cites W3159883015 @default.
• W4386319762 cites W3190709983 @default.
• W4386319762 cites W3192811346 @default.
• W4386319762 cites W3193632582 @default.
• W4386319762 cites W3193944859 @default.
• W4386319762 cites W3197489851 @default.
• W4386319762 cites W3211078463 @default.
• W4386319762 cites W4200129877 @default.
• W4386319762 cites W4200268685 @default.
• W4386319762 cites W4226278337 @default.
• W4386319762 cites W4281611922 @default.
• W4386319762 cites W4366595127 @default.
• W4386319762 cites W968982197 @default.
• W4386319762 doi "https://doi.org/10.1016/j.phymed.2023.155062" @default.
• W4386319762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37683586" @default.
• W4386319762 hasPublicationYear "2023" @default.
• W4386319762 type Work @default.
• W4386319762 citedByCount "0" @default.
• W4386319762 crossrefType "journal-article" @default.
• W4386319762 hasAuthorship W4386319762A5003580554 @default.
• W4386319762 hasAuthorship W4386319762A5011435455 @default.
• W4386319762 hasAuthorship W4386319762A5028121388 @default.
• W4386319762 hasAuthorship W4386319762A5030921116 @default.
• W4386319762 hasAuthorship W4386319762A5035182164 @default.
• W4386319762 hasAuthorship W4386319762A5063103450 @default.
• W4386319762 hasConcept C104317684 @default.
• W4386319762 hasConcept C121608353 @default.
• W4386319762 hasConcept C1491633281 @default.
• W4386319762 hasConcept C150903083 @default.
• W4386319762 hasConcept C207001950 @default.
• W4386319762 hasConcept C2777088508 @default.
• W4386319762 hasConcept C2779013556 @default.
• W4386319762 hasConcept C2780394083 @default.
• W4386319762 hasConcept C29537977 @default.
• W4386319762 hasConcept C502942594 @default.
• W4386319762 hasConcept C54355233 @default.
• W4386319762 hasConcept C55493867 @default.
• W4386319762 hasConcept C62112901 @default.
• W4386319762 hasConcept C86339819 @default.
• W4386319762 hasConcept C86803240 @default.
• W4386319762 hasConceptScore W4386319762C104317684 @default.
• W4386319762 hasConceptScore W4386319762C121608353 @default.
• W4386319762 hasConceptScore W4386319762C1491633281 @default.
• W4386319762 hasConceptScore W4386319762C150903083 @default.
• W4386319762 hasConceptScore W4386319762C207001950 @default.
• W4386319762 hasConceptScore W4386319762C2777088508 @default.
• W4386319762 hasConceptScore W4386319762C2779013556 @default.
• W4386319762 hasConceptScore W4386319762C2780394083 @default.
• W4386319762 hasConceptScore W4386319762C29537977 @default.
• W4386319762 hasConceptScore W4386319762C502942594 @default.
• W4386319762 hasConceptScore W4386319762C54355233 @default.
• W4386319762 hasConceptScore W4386319762C55493867 @default.
• W4386319762 hasConceptScore W4386319762C62112901 @default.
• W4386319762 hasConceptScore W4386319762C86339819 @default.
• W4386319762 hasConceptScore W4386319762C86803240 @default.
• W4386319762 hasLocation W43863197621 @default.
• W4386319762 hasLocation W43863197622 @default.
• W4386319762 hasOpenAccess W4386319762 @default.
• W4386319762 hasPrimaryLocation W43863197621 @default.
• W4386319762 hasRelatedWork W1983339443 @default.
• W4386319762 hasRelatedWork W2006761645 @default.
• W4386319762 hasRelatedWork W2358524972 @default.
• W4386319762 hasRelatedWork W2791088259 @default.
• W4386319762 hasRelatedWork W2890558057 @default.
• W4386319762 hasRelatedWork W2998402275 @default.

• next